FDA’s Interim Access Policy for Peptides: What It Means for Your Telehealth Peptide Program

For the last three years, building a telehealth peptide program meant operating in a gray zone. Many of the most requested peptides sat on the FDA’s “do not compound” list, and demand moved to gray-market “research use only” vials instead. On October 28, 2026, that changed. The federal government released an interim policy that gives […]